<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en" article-type="rapid-communication" dtd-version="2.3">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">molbank</journal-id>
      <journal-title>Molbank</journal-title>
      <abbrev-journal-title abbrev-type="publisher">Molbank</abbrev-journal-title>
      <abbrev-journal-title abbrev-type="pubmed">Molbank</abbrev-journal-title>
      <issn pub-type="epub">1422-8599</issn>
      <publisher>
        <publisher-name>MDPI</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.3390/M885</article-id>
      <article-id pub-id-type="publisher-id">molbank-2016-M885</article-id>
      <article-categories>
        <subj-group>
          <subject>Short Note</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>9-(4-Methoxyquinazolin-2-yl)-9<italic>H</italic>-purin-6-amine</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Vlachou</surname>
            <given-names>Ioanna</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kourtidou</surname>
            <given-names>Eleni</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Papasotiriou</surname>
            <given-names>Ioannis</given-names>
          </name>
          <xref rid="c1-molbank-2016-M885" ref-type="corresp">*</xref>
        </contrib>
        <contrib contrib-type="editor">
          <name>
            <surname>Haider</surname>
            <given-names>Norbert</given-names>
          </name>
          <role>Academic Editor</role>
        </contrib>
      </contrib-group>
      <aff id="af1-molbank-2016-M885">R.G.C.C. (Research Genetic Cancer Centre) Ltd., Industrial Area of Florina, GR 53100 Florina, Greece; <email>vlachou.ioanna@rgcc-genlab.com</email> (I.V.); <email>kourtidou.eleni@rgcc-genlab.com</email> (E.K.)</aff>
      <author-notes>
        <corresp id="c1-molbank-2016-M885"><label>*</label>Correspondence: <email>papasotiriou.ioannis@rgcc-genlab.com</email>; Tel.: +30-23850-41950; Fax: +30-23850-41931</corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>19</day>
        <month>01</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="collection">
        <month>03</month>
        <year>2016</year>
      </pub-date>
      <volume>2016</volume>
      <issue>1</issue>
      <elocation-id>M885</elocation-id>
      <history>
        <date date-type="received">
          <day>18</day>
          <month>12</month>
          <year>2015</year>
        </date>
        <date date-type="accepted">
          <day>11</day>
          <month>01</month>
          <year>2016</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; 2016 by the authors; licensee MDPI, Basel, Switzerland.</copyright-statement>
        <copyright-year>2016</copyright-year>
        <license>
          <p>This article is an open access article distributed under the terms and conditions of the Creative Commons by Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).</p>
        </license>
      </permissions>
      <abstract>
        <p>A novel hybrid consisting of quinazoline and adenine moieties has been synthesized as a precursor of a potential biologically active target compound. The structure of 9-(4-methoxyquinazolin-2-yl)-9<italic>H</italic>-purin-6-amine (<bold>2</bold>) was characterized and confirmed using the following spectroscopic methods: LC-UV-MS, <sup>1</sup>H-NMR, <sup>13</sup>C-NMR and HSQC-NMR.</p>
      </abstract>
      <kwd-group>
        <kwd>9-substituted adenine</kwd>
        <kwd>quinazoline</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec id="sec1-molbank-2016-M885" sec-type="intro">
      <title>1. Introduction</title>
      <p>Various <italic>N</italic>-aryl nucleobases are known for their antitumor [<xref ref-type="bibr" rid="B1-molbank-2016-M885">1</xref>,<xref ref-type="bibr" rid="B2-molbank-2016-M885">2</xref>] and antimicrobial [<xref ref-type="bibr" rid="B3-molbank-2016-M885">3</xref>] activity. A significant number of <italic>N</italic>9-arylpurines have been reported to act as agonists or antagonists for several receptors and enzymes [<xref ref-type="bibr" rid="B4-molbank-2016-M885">4</xref>]. In particular, a variety of 9-substituted adenines have been published for their interaction with adenosine receptors, which are found to be upregulated in various tumor cells [<xref ref-type="bibr" rid="B5-molbank-2016-M885">5</xref>]. On the other hand, quinazolines as heterocyclic compounds containing two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring [<xref ref-type="bibr" rid="B6-molbank-2016-M885">6</xref>], are considered to be a "privileged structure" for drug development [<xref ref-type="bibr" rid="B7-molbank-2016-M885">7</xref>]. Over the years, medicinal chemists have synthesized a variety of quinazoline derivatives with different biological activities (anti-cancer [<xref ref-type="bibr" rid="B8-molbank-2016-M885">8</xref>,<xref ref-type="bibr" rid="B9-molbank-2016-M885">9</xref>,<xref ref-type="bibr" rid="B10-molbank-2016-M885">10</xref>,<xref ref-type="bibr" rid="B11-molbank-2016-M885">11</xref>], antimicrobial [<xref ref-type="bibr" rid="B12-molbank-2016-M885">12</xref>,<xref ref-type="bibr" rid="B13-molbank-2016-M885">13</xref>,<xref ref-type="bibr" rid="B14-molbank-2016-M885">14</xref>,<xref ref-type="bibr" rid="B15-molbank-2016-M885">15</xref>], <italic>etc.</italic>) by inserting various active groups to the quinazoline moiety using developing synthetic methods [<xref ref-type="bibr" rid="B16-molbank-2016-M885">16</xref>].</p>
      <p>Taking into consideration the value of both adenine and quinazoline entities, we have designed a route for the synthesis of a target compound consisting the conjugation of these moieties. <italic>In silico</italic> modeling of the coupled molecule which assess the binding affinity as well as the potential inhibitory effect on specific binding sites of human proteins, reveals a promising result that this compound can be used as precursor molecule for medicinal chemical structures. This coupling is achieved by regioselective <italic>N</italic>-arylation via nucleophilic aromatic substitution (SN<sub>Ar</sub>) [<xref ref-type="bibr" rid="B17-molbank-2016-M885">17</xref>]. In this paper we report the synthesis of 9-(4-methoxyquinazolin-2-yl)-9<italic>H</italic>-purin-6-amine which constitutes an intermediate of the aforementioned route (<xref ref-type="scheme" rid="molbank-2016-M885-f001">Scheme 1</xref>).</p>
    </sec>
    <sec id="sec2-molbank-2016-M885">
      <title>2. Experimental Section</title>
      <sec id="sec2dot1-molbank-2016-M885">
        <title>2.1. General Methods</title>
        <p>All reagents were used as received without further purification unless stated otherwise. Flash chromatography was performed on silica gel 60, 0.04&#x2013;0.063 mm (Zeochem, Uetikon, Switzerland). Melting points were measured on a Stuart SMP30 melting point apparatus (Bibby Scientific Limited (Group HQ), Stone, UK) and are uncorrected. HPLC was carried out on an Agilent 1200 system (Agilent Technology, Santa Clara, CA, USA), using the column: Grace Prevail 5 &#x3BC;m C18, 4.6 mm &#xD7; 250 mm (Grace Alltech, Breda, NL, USA). Mass analysis was performed on a Bruker MicrOTOF (Bruker Daltonics, Bremen, Germany). ESI was used for ionization and the spectrum was recorded in positive mode. NMR spectra (<sup>1</sup>H, <sup>13</sup>C, <sup>13</sup>C-HSQC) were recorded on a Bruker 500 MHz Avance III system (Bruker Biospin, Karlsruhe, Germany) equipped with 5 mm cryoprobe, CPTCI (<sup>1</sup>H-<sup>13</sup>C/<sup>15</sup>N/<sup>2</sup>H + Z-gradients). Chemical shifts are given in ppm and <italic>J</italic> values in Hertz (Hz). Solids were dried in a Memmert UNB 400 oven (Memmert GmbH, Schwabach, Germany).</p>
        <p>2-chloro-4-methoxyquinazoline (<bold>1</bold>) has been synthesized according to reported methods [<xref ref-type="bibr" rid="B18-molbank-2016-M885">18</xref>,<xref ref-type="bibr" rid="B19-molbank-2016-M885">19</xref>]. Spectroscopic results and physical properties are consistent with the literature [<xref ref-type="bibr" rid="B20-molbank-2016-M885">20</xref>]. </p>
        <fig id="molbank-2016-M885-f001" position="float">
          <object-id pub-id-type="pii">molbank-2016-M885-f001_Scheme 1</object-id>
          <label>Scheme 1</label>
          <caption>
            <p>The synthesis of 9-(4-methoxyquinazolin-2-yl)-9<italic>H</italic>-purin-6-amine.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molbank-2016-M885-g001.tif"/>
        </fig>
      </sec>
      <sec id="sec2dot2-molbank-2016-M885">
        <title>2.2. Synthesis of 9-(4-Methoxyquinazolin-2-yl)-9H-purin-6-amine <italic>(<bold>2</bold>)</italic></title>
        <p>To a well-grounded mixture of adenine (1.3512 g, 10 mmol), 2-chloro-4-methoxyquinazoline (2.5104 g, 13 mmol), cesium carbonate (3.2612 g, 10 mmol) and silica gel (3.5 g) was added 20 mL of dry DMSO under inert atmosphere. The solution was stirred at 100 &#xB0;C for 2 h and then it was poured into ice cold water and filtered. The desired product was anchored on the silica gel and was purified by flash chromatography. On elution with chloroform-methanol 7:1 (R<sub>f</sub> = 0.38), 9-(4-methoxyquinazolin-2-yl)-9<italic>H</italic>-purin-6-amine was obtained as light yellow solid (m.p. = 303 &#xB0;C) in 37% yield. The relatively modest yield was expected as 2-chloro-4-methoxyquinazoline is considered a non-activated substrate for nucleophilic aromatic substitution.</p>
        <p><sup>1</sup>H-NMR (500 MHz, CDCl<sub>3</sub>) &#x3B4; 4.36 (s, <italic>J</italic> = 2.99 Hz, 3H, OCH<sub>3</sub>), 7.65 (t, <italic>J</italic> = 1.00 Hz, 1H, Ar-H), 7.87 (d, <italic>J</italic> = 0.99 Hz, 1H, Ar-H), 7.96 (t, <italic>J</italic> = 1.00 Hz, 1H, Ar-H), 8.25 (d, <italic>J</italic> = 0.99 Hz, 1H, Ar-H), 8.41 (s, <italic>J</italic> = 0.98 Hz, 1H, N=C<italic>H</italic>-N), 9.38 (s, <italic>J</italic> = 0.98 Hz, 1H, N=C<italic>H</italic>-N); <sup>13</sup>C-NMR (500 MHz, CDCl<sub>3</sub>) &#x3B4; 55.6 (C=O), 110.0 (C12), 115.1 (C3), 124.6 (C7), 126.1 (C5), 127.7 (C4), 135.7 (C6), 145.4 (C14), 150.1 (C8), 150.4 (C11), 152.9 (C13), 154.3 (C10), 161.3 (C2), 169.2 (C9); LC-MS (ESI): [M + H]<sup>+</sup> calculated for C<sub>14</sub>H<sub>11</sub>N<sub>7</sub>O = 294.1094; found 294.1090. Copies of all spectra (<xref ref-type="app" rid="app1-molbank-2016-M885">Figures S1&#x2013;S7</xref>) are provided in the <xref ref-type="app" rid="app1-molbank-2016-M885">Supplementary Materials</xref>.</p>
      </sec>
    </sec>
   </body>
  <back>
    <app-group>
	<app id="app1-molbank-2016-M885">
      <title>Supplementary Materials</title>
      <p>The molefiles and the other supplementary materials can be found at <uri>http://www.mdpi.com/1422-8599/2016/1/M885</uri>.</p>
    </app>
	</app-group>
   <notes>
      <title>Author Contributions</title>
      <p>All authors contributed equally to both experimental and writing work.</p>
    </notes>
    <notes>
      <title>Conflicts of Interest</title>
      <p>The authors declare no conflict of interest.</p>
    </notes>
    <ref-list>
      <title>References</title>
      <ref id="B1-molbank-2016-M885">
        <label>1.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Koppel</surname>
              <given-names>H.C.</given-names>
            </name>
            <name>
              <surname>Robins</surname>
              <given-names>R.K.</given-names>
            </name>
          </person-group>
          <article-title>Potential Purine Antagonists. XI. Synthesis of some 9-aryl(alkyl)-2,6-disubstituted purines</article-title>
          <source>J. Am. Chem. Soc.</source>
          <year>1958</year>
          <volume>80</volume>
          <fpage>2751</fpage>
          <lpage>2755</lpage>
          <pub-id pub-id-type="doi">10.1021/ja01544a044</pub-id>
        </citation>
      </ref>
      <ref id="B2-molbank-2016-M885">
        <label>2.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Koppel</surname>
              <given-names>H.C.</given-names>
            </name>
            <name>
              <surname>O&#x2019;Brien</surname>
              <given-names>D.E.</given-names>
            </name>
            <name>
              <surname>Robins</surname>
              <given-names>R.K.</given-names>
            </name>
          </person-group>
          <article-title>Potential Purine Antagonists. XIX. Synthesis of Some 9-Alkyl (aryl)-2-amino-6-substituted Purines and Related V-Triazolo [d] pyrimidines</article-title>
          <source>J. Am. Chem. Soc.</source>
          <year>1959</year>
          <volume>81</volume>
          <fpage>3046</fpage>
          <lpage>3051</lpage>
          <pub-id pub-id-type="doi">10.1021/ja01521a034</pub-id>
        </citation>
      </ref>
      <ref id="B3-molbank-2016-M885">
        <label>3.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Basyouni</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Hosni</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Helmy</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis and antimicrobial activity of some new 6-substituted 9-arylpurine derivatives</article-title>
          <source>Egypt. J. Chem.</source>
          <year>1999</year>
          <volume>42</volume>
          <fpage>587</fpage>
          <lpage>598</lpage>
        </citation>
      </ref>
      <ref id="B4-molbank-2016-M885">
        <label>4.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Thompson</surname>
              <given-names>R.D.</given-names>
            </name>
            <name>
              <surname>Secunda</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Daly</surname>
              <given-names>J.W.</given-names>
            </name>
            <name>
              <surname>Olsson</surname>
              <given-names>R.A.</given-names>
            </name>
          </person-group>
          <article-title><italic>N</italic>6,9-Disubstituted adenines: Potent, selective antagonists at the A1 adenosine receptor</article-title>
          <source>J. Med. Chem.</source>
          <year>1991</year>
          <volume>34</volume>
          <fpage>2877</fpage>
          <lpage>2882</lpage>
          <pub-id pub-id-type="doi">10.1021/jm00113a029</pub-id>
          <pub-id pub-id-type="pmid">1895305</pub-id>
        </citation>
      </ref>
      <ref id="B5-molbank-2016-M885">
        <label>5.</label>
        <citation citation-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Fishman</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Bar-Yehuda</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Synowitz</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Powell</surname>
              <given-names>J.D.</given-names>
            </name>
            <name>
              <surname>Klotz</surname>
              <given-names>K.N.</given-names>
            </name>
            <name>
              <surname>Gessi</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Borea</surname>
              <given-names>P.A.</given-names>
            </name>
          </person-group>
          <article-title>Adenosine Receptors and Cancer</article-title>
          <source>Adenosine Receptors in Health and Disease</source>
          <person-group person-group-type="editor">
            <name>
              <surname>Wilson</surname>
              <given-names>C.N.</given-names>
            </name>
			<name>
              <surname>Mustafa</surname>
              <given-names>S.J.</given-names>
            </name>
          </person-group>
          <publisher-name>Springer</publisher-name>
          <publisher-loc>Berlin, Germany</publisher-loc>
          <year>2009</year>
          <volume>Volume 193</volume>
          <fpage>399</fpage>
          <lpage>441</lpage>
        </citation>
      </ref>
      <ref id="B6-molbank-2016-M885">
        <label>6.</label>
        <citation citation-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Armarego</surname>
              <given-names>W.L.F.</given-names>
            </name>
            <name>
              <surname>Hitchings</surname>
              <given-names>G.H.</given-names>
            </name>
            <name>
              <surname>Elio</surname>
              <given-names>G.B.</given-names>
            </name>
          </person-group>
          <article-title>Quinazolines</article-title>
          <source>The Chemistry of Heterocyclic Compounds, Fused Pyrimidines., Part. I</source>
          <publisher-name>Wiley and Sons</publisher-name>
          <publisher-loc>Chichester, UK</publisher-loc>
          <year>1967</year>
          <volume>Volume 24</volume>
          <fpage>11</fpage>
          <lpage>38</lpage>
        </citation>
      </ref>
      <ref id="B7-molbank-2016-M885">
        <label>7.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Horton</surname>
              <given-names>D.A.</given-names>
            </name>
            <name>
              <surname>Bourne</surname>
              <given-names>G.T.</given-names>
            </name>
            <name>
              <surname>Smythe</surname>
              <given-names>M.L.</given-names>
            </name>
          </person-group>
          <article-title>The Combinatorial Synthesis of Bicyclic Privileged Structures or Privileged Substructures</article-title>
          <source>Chem. Rev.</source>
          <year>2003</year>
          <volume>103</volume>
          <fpage>893</fpage>
          <lpage>930</lpage>
          <pub-id pub-id-type="doi">10.1021/cr020033s</pub-id>
          <pub-id pub-id-type="pmid">12630855</pub-id>
        </citation>
      </ref>
      <ref id="B8-molbank-2016-M885">
        <label>8.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chandregowda</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Kush</surname>
              <given-names>A.K.</given-names>
            </name>
            <name>
              <surname>Chandrasekara Reddy</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis and <italic>in vitro</italic> antitumor activities of novel 4-anilinoquinazoline derivatives</article-title>
          <source>Eur. J. Med. Chem.</source>
          <year>2009</year>
          <volume>44</volume>
          <fpage>3046</fpage>
          <lpage>3055</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ejmech.2008.07.023</pub-id>
          <pub-id pub-id-type="pmid">18771819</pub-id>
        </citation>
      </ref>
      <ref id="B9-molbank-2016-M885">
        <label>9.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Al-Rashood</surname>
              <given-names>S.T.</given-names>
            </name>
            <name>
              <surname>Aboldahab</surname>
              <given-names>I.A.</given-names>
            </name>
            <name>
              <surname>Nagi</surname>
              <given-names>M.N.</given-names>
            </name>
            <name>
              <surname>Abouzeid</surname>
              <given-names>L.A.</given-names>
            </name>
            <name>
              <surname>Abdel-Aziz</surname>
              <given-names>A.A.</given-names>
            </name>
            <name>
              <surname>Abdel-Hamide</surname>
              <given-names>S.G.</given-names>
            </name>
            <name>
              <surname>Youssef</surname>
              <given-names>K.M.</given-names>
            </name>
            <name>
              <surname>Al-Obaid</surname>
              <given-names>A.M.</given-names>
            </name>
            <name>
              <surname>El-Subbagh</surname>
              <given-names>H.I.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis, dihydrofolate reductase inhibition, antitumor testing, and molecular modeling study of some new 4(<italic>3H</italic>)-quinazolinone analogs</article-title>
          <source>Bioorg. Med. Chem.</source>
          <year>2006</year>
          <volume>14</volume>
          <fpage>8608</fpage>
          <lpage>8621</lpage>
          <pub-id pub-id-type="doi">10.1016/j.bmc.2006.08.030</pub-id>
          <pub-id pub-id-type="pmid">16971132</pub-id>
        </citation>
      </ref>
      <ref id="B10-molbank-2016-M885">
        <label>10.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vasdev</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Dorff</surname>
              <given-names>P.N.</given-names>
            </name>
            <name>
              <surname>Gibbs</surname>
              <given-names>A.R.</given-names>
            </name>
            <name>
              <surname>Nandanan</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Reid</surname>
              <given-names>L.M.</given-names>
            </name>
            <name>
              <surname>Neil</surname>
              <given-names>J.P.</given-names>
            </name>
            <name>
              <surname>VanBrocklin</surname>
              <given-names>H.F.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis of 6-acrylamido-4-(2-[<sup>18</sup>F]fluoroanilino)quinazoline: A prospective irreversible EGFR binding probe</article-title>
          <source>J. Lablelled Compd. Rad.</source>
          <year>2005</year>
          <volume>48</volume>
          <fpage>109</fpage>
          <lpage>115</lpage>
          <pub-id pub-id-type="doi">10.1002/jlcr.903</pub-id>
        </citation>
      </ref>
      <ref id="B11-molbank-2016-M885">
        <label>11.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wakeling</surname>
              <given-names>A.E.</given-names>
            </name>
            <name>
              <surname>Guy</surname>
              <given-names>S.P.</given-names>
            </name>
            <name>
              <surname>Woodburn</surname>
              <given-names>J.R.</given-names>
            </name>
            <name>
              <surname>Ashton</surname>
              <given-names>S.E.</given-names>
            </name>
            <name>
              <surname>Curry</surname>
              <given-names>B.J.</given-names>
            </name>
            <name>
              <surname>Barker</surname>
              <given-names>A.J.</given-names>
            </name>
            <name>
              <surname>Gibson</surname>
              <given-names>K.H.</given-names>
            </name>
          </person-group>
          <article-title>ZD1839 (Iressa): An orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy</article-title>
          <source>Cancer Res.</source>
          <year>2002</year>
          <volume>62</volume>
          <fpage>5749</fpage>
          <lpage>5754</lpage>
          <pub-id pub-id-type="pmid">12384534</pub-id>
        </citation>
      </ref>
      <ref id="B12-molbank-2016-M885">
        <label>12.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rohini</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Muralidhar Reddy</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Shanker</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Hu</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Ravinder</surname>
              <given-names>V.</given-names>
            </name>
          </person-group>
          <article-title>Antimicrobial study of newly synthesized 6-substituted indolo[1,2-c]quinazolines</article-title>
          <source>Eur. J. Med. Chem.</source>
          <year>2010</year>
          <volume>45</volume>
          <fpage>1200</fpage>
          <lpage>1205</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ejmech.2009.11.038</pub-id>
          <pub-id pub-id-type="pmid">20005020</pub-id>
        </citation>
      </ref>
      <ref id="B13-molbank-2016-M885">
        <label>13.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Antipenko</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Karpenko</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Kovalenko</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Katsev</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Komarovska-Porokhnyavets</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Novikov</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Chekotilo</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis of new 2-thio-[1,2,4]triazolo[1,5-c]quinazoline derivatives and its antimicrobial activity</article-title>
          <source>Chem. Pharm. Bull.</source>
          <year>2009</year>
          <volume>57</volume>
          <fpage>580</fpage>
          <lpage>585</lpage>
          <pub-id pub-id-type="doi">10.1248/cpb.57.580</pub-id>
          <pub-id pub-id-type="pmid">19483337</pub-id>
        </citation>
      </ref>
      <ref id="B14-molbank-2016-M885">
        <label>14.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jatav</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Kashaw</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Mishra</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis and antimicrobial activity of some new 3&#x2013;[5-(4-substituted)phenyl-1,3,4-oxadiazole-2yl]-2-styrylquinazoline-4(3<italic>H</italic>)-ones</article-title>
          <source>Med. Chem. Res.</source>
          <year>2008</year>
          <volume>17</volume>
          <fpage>205</fpage>
          <lpage>211</lpage>
          <pub-id pub-id-type="doi">10.1007/s00044-007-9047-2</pub-id>
        </citation>
      </ref>
      <ref id="B15-molbank-2016-M885">
        <label>15.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Aly</surname>
              <given-names>A.A.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis of novel quinazoline derivatives as antimicrobial agents</article-title>
          <source>Chin. J. Chem.</source>
          <year>2003</year>
          <volume>21</volume>
          <fpage>339</fpage>
          <lpage>346</lpage>
          <pub-id pub-id-type="doi">10.1002/cjoc.20030210324</pub-id>
        </citation>
      </ref>
      <ref id="B16-molbank-2016-M885">
        <label>16.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Gao</surname>
              <given-names>F.</given-names>
            </name>
          </person-group>
          <article-title>Quinazoline derivatives: Synthesis and bioactivities</article-title>
          <source>Chem. Cent. J.</source>
          <year>2013</year>
          <volume>7</volume>
          <elocation-id>95</elocation-id>
          <pub-id pub-id-type="doi">10.1186/1752-153X-7-95</pub-id>
          <pub-id pub-id-type="pmid">23731671</pub-id>
        </citation>
      </ref>
      <ref id="B17-molbank-2016-M885">
        <label>17.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Khalafi-Nezland</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Zare</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Parhami</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Regioselective <italic>N</italic>-arylation of some pyrimidine and purine nucleobases</article-title>
          <source>Syn. Commun.</source>
          <year>2006</year>
          <volume>36</volume>
          <fpage>3549</fpage>
          <lpage>3562</lpage>
          <pub-id pub-id-type="doi">10.1080/00397910600943535</pub-id>
        </citation>
      </ref>
      <ref id="B18-molbank-2016-M885">
        <label>18.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lange</surname>
              <given-names>N.A.</given-names>
            </name>
            <name>
              <surname>Sheibley</surname>
              <given-names>F.E.</given-names>
            </name>
          </person-group>
          <article-title>Quinazolines. II. The interaction of 2,4-dichloroquinazoline in alcohol with salts and bases</article-title>
          <source>J. Am. Chem. Soc.</source>
          <year>1931</year>
          <volume>53</volume>
          <fpage>3867</fpage>
          <lpage>3875</lpage>
          <pub-id pub-id-type="doi">10.1021/ja01361a030</pub-id>
        </citation>
      </ref>
      <ref id="B19-molbank-2016-M885">
        <label>19.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lange</surname>
              <given-names>N.A.</given-names>
            </name>
            <name>
              <surname>Roush</surname>
              <given-names>W.E.</given-names>
            </name>
            <name>
              <surname>Asbeck</surname>
              <given-names>H.J.</given-names>
            </name>
          </person-group>
          <article-title>Quinazolines. I. The interaction of 2,4-dichloroquinazoline with sodium alcoholates and sodium phenates with the replacement of one halogen to form halogen-oxygen ethers</article-title>
          <source>J. Am. Chem. Soc.</source>
          <year>1930</year>
          <volume>52</volume>
          <fpage>3696</fpage>
          <lpage>3702</lpage>
          <pub-id pub-id-type="doi">10.1021/ja01372a041</pub-id>
        </citation>
      </ref>
      <ref id="B20-molbank-2016-M885">
        <label>20.</label>
        <citation citation-type="patent">
          <person-group person-group-type="author">
            <name>
              <surname>Almirall</surname>
              <given-names>S.A.</given-names>
            </name>
            <name>
              <surname>Eastwood</surname>
              <given-names>P.R.</given-names>
            </name>
            <name>
              <surname>Gonzalez Rodriguez</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Bach Tana</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Pages Santacana</surname>
              <given-names>L.M.</given-names>
            </name>
            <name>
              <surname>Taltavull Moll</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Caturla Javaloyes</surname>
              <given-names>J.F.</given-names>
            </name>
            <name>
              <surname>Matassa</surname>
              <given-names>V.G.</given-names>
            </name>
          </person-group>
          <article-title>Imidazopyridine Derivatives as JAK Inhibitors</article-title>
          <patent>Patent WO2011/76419 A1</patent>
          <day>29</day>
          <month>June</month>
		  <year>2011</year>
        </citation>
      </ref>
    </ref-list>
  </back>
</article>
